Zacks Investment Research
04 Aug 2026, 18:46 UTC · 2h ago
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
04 Aug 2026, 18:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Jazz Pharmaceuticals raised its 2026 sales outlook following a 16% year-over-year revenue increase to $1.21 billion. — Guidance raises and revenue beats are primary drivers of positive stock price action.
+0.60Xywav sales grew 13% to $471 million, with the company adding 525 net patients in Q2, the highest quarterly increase in a year. — Strong growth in a core product and increasing patient acquisition suggest sustainable long-term revenue growth.
+0.40Jazz Pharmaceuticals missed Q2 2026 adjusted EPS estimates, reporting $5.71 against a consensus of $6.04. — An earnings miss is typically negative, though in this case it was offset by the revenue beat and guidance raise.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
High-sodium oxybate authorized generic royalty revenues decreased 22% year-over-year to $42 million. — Declining royalty streams indicate a loss of income in a specific product segment.
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
